Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
January 05, 2023 07:30 ET
|
Intellia Therapeutics, Inc.
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in...
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
November 30, 2022 21:29 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
November 30, 2022 16:37 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
November 12, 2022 16:30 ET
|
Intellia Therapeutics, Inc.
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest...
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
November 05, 2022 16:00 ET
|
Intellia Therapeutics, Inc.
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy...
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 03, 2022 07:30 ET
|
Intellia Therapeutics, Inc.
Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively,...
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
October 31, 2022 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
October 27, 2022 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Intellia Therapeutics to Present at October Healthcare Investor Conferences
September 26, 2022 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
September 16, 2022 07:15 ET
|
Intellia Therapeutics, Inc.
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses,...